#ASCO25: Strand Therapeutics reports promising start for mRNA cancer therapynews2025-05-28T11:02:48+00:00May 28th, 2025|Endpoints News|
InflaRx cans Gohibic development after skin disease trial stopped for futilitynews2025-05-28T09:23:55+00:00May 28th, 2025|Endpoints News|
Boundless Bio changes plans for cancer drug after toxicity issuesnews2025-05-27T15:37:35+00:00May 27th, 2025|Endpoints News|
Gilgamesh’s psychedelic shows rapid effect in depression studynews2025-05-27T14:18:22+00:00May 27th, 2025|Endpoints News|
Prothena’s amyloidosis drug flops again, spending and staff cuts are on the waynews2025-05-27T11:05:58+00:00May 27th, 2025|Endpoints News|
#ASCO25: Kura spells out pivotal AML trial win as it gears up to compete with Syndaxnews2025-05-23T14:47:29+00:00May 23rd, 2025|Endpoints News|
Gilead notches another Phase 3 win for Trodelvy in triple-negative breast cancernews2025-05-23T12:30:20+00:00May 23rd, 2025|Endpoints News|
#ASCO25: Volastra unveils first human data of its oral KIF18A drugnews2025-05-23T08:44:23+00:00May 23rd, 2025|Endpoints News|
#ASCO25: Merus’ Phase 2 overall survival data reach ‘home run’ scenario — analystnews2025-05-22T21:30:50+00:00May 22nd, 2025|Endpoints News|
#ASCO25: Roche confirms OS benefit for PI3K inhibitor Itovebi in breast cancernews2025-05-22T21:00:30+00:00May 22nd, 2025|Endpoints News|
